Patents by Inventor Frank B. Gelder
Frank B. Gelder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10232010Abstract: The present invention relates to an immunostimulant and to the use of an immunostimulant in the form of a cross-linked muramyl dipeptide microparticle in the treatment of radiation exposure, radiation poisoning, and mitigating the toxic effects of radiotherapy.Type: GrantFiled: September 30, 2009Date of Patent: March 19, 2019Assignee: Innate Immunotherapeutics LimitedInventors: Frank B. Gelder, Gillian Alison Webster
-
Patent number: 9950025Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of muramyl dipeptide, and their use in the treatment of neoplastic disease.Type: GrantFiled: August 15, 2016Date of Patent: April 24, 2018Assignee: Innate Immunotherapeutics LimitedInventors: Frank B. Gelder, Gillian Alison Webster
-
Publication number: 20160354424Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of muramyl dipeptide, and their use in the treatment of neoplastic disease.Type: ApplicationFiled: August 15, 2016Publication date: December 8, 2016Inventors: Frank B. Gelder, Gillian Alison Webster
-
Patent number: 9415061Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of murmyl dipeptide, and their use in the treatment of neoplastic disease.Type: GrantFiled: April 1, 2009Date of Patent: August 16, 2016Assignee: Innate Immunotherapeutics LimitedInventors: Frank B Gelder, Gillian Alison Webster
-
Patent number: 8709448Abstract: The present invention is concerned with novel immunostimulant microparticle compositions and their use as anti-infective agents in the treatment of bacterial and viral infections.Type: GrantFiled: April 1, 2009Date of Patent: April 29, 2014Assignee: Innate Immunotherapeutics Ltd.Inventors: Frank B Gelder, Gillian Alison Webster
-
Patent number: 8389479Abstract: Disclosed are novel compositions and methods for the treatment of Multiple Sclerosis (MS), and in particular immunostimulatory compositions comprising muramyl dipeptide microparticles for use, e.g., in the treatment of MS.Type: GrantFiled: December 16, 2009Date of Patent: March 5, 2013Assignee: Innate Immunotherapeutics LimitedInventors: Frank B. Gelder, Gillian Alison Webster
-
Patent number: 8110203Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections. The present invention is also directed to chemical conjugates (herein referred to as MDP) adjuvant microparticle-antigen conjugates) that have a muramyl dipeptide backbone crosslinked into a microparticle capable of binding to the cell surface of Antigen Presenting Cells (APCs), to which is covalently attached one or more molecules having a reactive carbonyl group (i.e.Type: GrantFiled: November 28, 2006Date of Patent: February 7, 2012Assignee: Innate Therapeutics LimitedInventor: Frank B. Gelder
-
Publication number: 20110236346Abstract: The present invention relates to an immunostimulant and to the use of an immunostimulant in the form of a cross-linked muramyl dipeptide microparticle in the treatment of radiation exposure, radiation poisoning, and mitigating the toxic effects of radiotherapy.Type: ApplicationFiled: September 30, 2009Publication date: September 29, 2011Applicant: INNATE THERAPEUTICS LIMITEDInventors: Frank B. Gelder, Gillian Alison Webster
-
Publication number: 20110165250Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of murmyl dipeptide, and their use in the treatment of neoplastic disease.Type: ApplicationFiled: April 1, 2009Publication date: July 7, 2011Inventors: Frank B. Gelder, Gillian Alison Webster
-
Publication number: 20110033494Abstract: The present invention is concerned with novel immunostimulant microparticle compositions and their use as anti-infective agents in the treatment of bacterial and viral infections.Type: ApplicationFiled: April 1, 2009Publication date: February 10, 2011Applicant: INNATE THERAPEUTICS LIMITEDInventors: Frank B. Gelder, Gillian Alison Webster
-
Publication number: 20100317589Abstract: Disclosed are novel compositions and methods for the treatment of Multiple Sclerosis (MS), and in particular immunostimulatory compositions comprising muramyl dipeptide microparticles for use, e.g., in the treatment of MS.Type: ApplicationFiled: December 16, 2009Publication date: December 16, 2010Inventors: Frank B. Gelder, Gillian Alison Webster
-
Publication number: 20040141996Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.Type: ApplicationFiled: October 28, 2003Publication date: July 22, 2004Inventor: Frank B. Gelder
-
Patent number: 6670181Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.Type: GrantFiled: November 5, 2001Date of Patent: December 30, 2003Assignee: Virionyx CorporationInventor: Frank B. Gelder
-
Publication number: 20020086034Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.Type: ApplicationFiled: November 5, 2001Publication date: July 4, 2002Applicant: Probe International Inc.Inventor: Frank B. Gelder
-
Patent number: 6335017Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.Type: GrantFiled: October 2, 2000Date of Patent: January 1, 2002Assignee: Probe International Inc.Inventor: Frank B. Gelder
-
Patent number: 6258599Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.Type: GrantFiled: January 14, 2000Date of Patent: July 10, 2001Assignee: Probe International Inc.Inventor: Frank B. Gelder
-
Patent number: 6043347Abstract: Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.Type: GrantFiled: October 10, 1997Date of Patent: March 28, 2000Assignee: Probe International Inc.Inventor: Frank B. Gelder
-
Patent number: 4315906Abstract: A highly purified, biologically active cold insoluble globulin (CIG) preparation is provided having specific opsonic activity of at least 1000 units per mg of CIG. Methods of purifying CIG using affinity antibody columns are described in which the biological activity of the purified CIG is greater than 95% of the activity of the starting material.The purified CIG can be radiolabelled and radiopharmaceutical preparations containing such CIG are useful as scanning agents for in vivo localizing of areas where CIG-binding determinants are expressed. Such areas include thrombi and damaged tissue such as burns, heart, liver, spleen, muscle, skin, kidney and the like. These areas of localized radiolabelled CIG can be visualized with a gamma camera.Type: GrantFiled: May 21, 1979Date of Patent: February 16, 1982Assignee: New England Nuclear CorporationInventor: Frank B. Gelder